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Blad polypeptide comprises residues 109–281 of Lupinus albus β-conglutin precursor. It
occurs naturally as a major subunit of an edible, 210 kDa oligomer which accumulates to
high levels, exclusively in the cotyledons of Lupinus seedlings between the 4th and 14th
day after the onset of germination. Blad-containing oligomer (BCO) exhibits a potent
and broad spectrum fungicide activity toward plant pathogens and is now on sale in
the US under the tradename FractureTM. In this work we demonstrate its antifungal
activity toward human pathogens and provide some insights on its mode of action. BCO
bioactivity was evaluated in eight yeast species and compared to that of amphotericin
B (AMB). BCO behaved similarly to AMB in what concerns both cellular inhibition and
cellular death. As a lectin, BCO binds strongly to chitin. In addition, BCO is known to
possess ‘exochitinase’ and ‘endochitosanase’ activities. However, no clear disruption
was visualized at the cell wall after exposure to a lethal BCO concentration, except
in cell buds. Immunofluorescent and immunogold labeling clearly indicate that BCO
enters the cell, and membrane destabilization was also demonstrated. The absence
of haemolytic activity, its biological origin, and its extraordinary antifungal activity are the
major outcomes of this work, and provide a solid background for a future application as
a new antifungal therapeutic drug. Furthermore, its predictable multisite mode of action
suggests a low risk of inducing resistance mechanisms, which are now a major problem
with other currently available antifungal drugs.
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INTRODUCTION
Fungal infections have become an important factor of morbidity and mortality and represent
an increasing burden on medical systems (Del Poeta, 2010; Huffnagle and Noverr, 2013), being
associated with unavoidable high mortality rates, similar to those caused by tuberculosis or malaria
(Brown et al., 2012).
Candida species are regarded as common components of the body microbiota in healthy
humans (Kathiravan et al., 2012) but are also responsible for candidaemia, an invasive fungal
infection associated with substantial morbidity, mortality and healthcare costs (Zaoutis et al., 2005;
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Bassetti et al., 2015), being among the top ten pathogens causing
bloodstream infections. Although C. albicans still remains the
most abundant and significant species associated with the disease,
other medically important species of Candida are rising (Klepser,
2011; Papon et al., 2013; Sardi et al., 2013; Won et al., 2015)
including C. glabrata, C. rugosa, C. parapsilosis, C. tropicalis, C.
dubliniensis, C. krusei, and C. lusitaniae ( Kathiravan et al., 2012;
Huffnagle and Noverr, 2013; León et al., 2014). A number of
factors may explain this gradual change in epidemiology, such as
severe immunosuppression or illness, prematurity, exposure to
broad-spectrum antibiotics and older patients (Sardi et al., 2013).
Some microorganisms are naturally resistant to certain
types of antifungal medications while other species, although
susceptible to a particular type of medication, have been
registered as developing resistance over time as a result of
improper antifungal use (Lortholary et al., 2011; Shah et al.,
2012). Therefore, new formulations of antifungals, combination
therapies and development of new bioactive compounds may
be the key for a better therapeutic outcome (Spampinato and
Leonardi, 2013), especially considering that antifungal research
is stagnant, when compared to other pathologies. In the last
decades, just a few new antifungal agents were unveiled and
they were mainly based on the structural modification of already
discovered drugs (Rubbiani et al., 2016).
Conventional therapies against fungi rely on a very limited
number of drugs (Myung and Klittich, 2015; Rubbiani et al.,
2016), from four different classes, and their antifungal activity
and mode of action is well reviewed in the literature: polyenes
(Patterson, 2006; Palacios et al., 2007; Denning and Hope, 2010;
Cornely et al., 2012; Mesa-Arango et al., 2014; Nett and Andes,
2016), azoles (Odds et al., 2003; Chapman et al., 2008; Cui
et al., 2015), echinocandins (Spampinato and Leonardi, 2013; Cui
et al., 2015), and pyrimidine analogs (Spampinato and Leonardi,
2013; Nett and Andes, 2016; Prasad et al., 2016). Despite the
introduction of new antifungal agents, the clinical outcomes for
most invasive fungal infections are far from ideal (Roemer and
Krysan, 2014). It is therefore imperative to continue the search
for different strategies to combat fungal infections (Spampinato
and Leonardi, 2013; Garrigues et al., 2016; Prasad et al., 2016).
Antimicrobial peptides and proteins are produced by
multicellular organisms as a defense mechanism against
competing pathogenic microbes (Selitrennikoff, 2001) and have
been considered as candidates for the development of novel
antimicrobial compounds (Fjell et al., 2012; Virágh et al., 2015;
Garrigues et al., 2016). A main hurdle that has hindered the
development of both natural and non-natural antimicrobial
peptides and proteins as therapeutic agents is the fact that many
of them exhibit antifungal activity in vitro (e.g., magainin), but
are only effective in vivo at very high, often toxic, levels (Darveau
et al., 1991; Zasloff, 2002). An additional difficulty associated to
the potential use of proteins is their inherent typical instability.
Currently there are only five antifungal peptides recorded as
having reached the clinical stage of the drug development cycle
(Duncan and O’Neil, 2013). The most prominent group within
the antifungal peptides are the defensins from plants, insects and
mammals (Hegedüs and Marx, 2013). Plant defensins, like Psd1
(Lobo et al., 2007), Nad1 (Van Der Weerden et al., 2008) and
MtDef4 (Sagaram et al., 2013) specifically interact with fungal
membrane sphingolipids and phospholipids, enter the cell and
interfere with nuclear and cytosolic proteins (Vriens et al., 2016).
A remarkable, novel antifungal 20.4 kDa polypeptide was
recently described. It is the major subunit of a 210 kDa
glyco-oligomer, termed Blad-containing oligomer (BCO), which
accumulates abundantly in Lupinus albus cotyledons between
days 4 and 12 after the onset of germination. The BCO appears
to reunite in a single molecule several selected characteristics,
making it a versatile, multifunctional protein (Monteiro et al.,
2010). Its extreme resistance to chemical inactivation but high
susceptibility to proteolytic attack (Monteiro et al., 2015),
associated to a powerful and broad spectrum antifungal activity
toward plant pathogens makes it a unique, flexible and
environmental friend active ingredient, now on sale in the US
under the tradename FractureTM.
In this work we demonstrate that the BCO also has a higher
inhibition potency for human pathogens than the azoles and
similar to amphotericin B (AMB) on a molar basis (Monteiro
et al., 2015), making the BCO a very promising clinical antifungal
agent. We also provide some insights on its highly complex and
multitarget mechanism of action.
MATERIALS AND METHODS
Microorganisms
Eight yeast strains were used, six belonging to Candida
spp., one Cryptococcus neoformans strain (CBS 132) and one
Saccharomyces cerevisiae strain (W303). Candida strains used
were C. albicans var. albicans (CBS 562), C. dubliniensis,
C. glabrata, C. lusitaneae, C. parapsilosis (PYCC 2597) and
C. tropicalis. [CBS – Centraalbureau voor Schimmelcultures;
PYCC – Portuguese Yeast Culture Collection; The other strains
were a kind gift of Institute of Microbiology, Faculty of Medicine
of the University of Coimbra (Paulo et al., 2009)]. All yeasts
were grown at 35◦C for 24 h, except for C. neoformans that
was grown for 72 h, in Glucose Yeast Peptone (GYP) medium
[0.5% (w/v) peptone, 0.5% (w/v) yeast extract, 2% (w/v) glucose,
1.5% (w/v) agar]. For the different experiments performed,
three media were used; RPMI 1640 (Applichem), pH 7.0,
supplemented with 2.08% (w/v) glucose and 6.9% (w/v) MOPS
[3-(N-morpholino)propanesulfonic acid]; YNB (Difco), pH 7.0,
supplemented with 2% (w/v) glucose and 0.1% (w/v) MOPS; and
PDB (DIFCO), buffered at pH 7.5.
Lupinus albus and BCO Purification
Dry seeds of Lupinus albus were germinated and grown in growth
chambers with a photoperiod of 16 h light/8 h dark at 18◦C, for
periods up to 10 days. The seed coats were removed and the intact
cotyledons were dissected from the axes and stored frozen at
−80◦C until needed. BCO is a breakdown product of β-conglutin
catabolism, and it was extracted and isolated from the cotyledons
of 8-days old seedlings as described by (Monteiro et al., 2015).
The protein corresponding to β-conglutin was purified by AKTA
anion exchange chromatography followed by AKTA gel filtration
chromatography as follows: the total globulin fraction was loaded
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on the Q-Sepharose column (Ø = 1 cm; h = 8 cm; flow
rate = 1.5 mL/min) previously equilibrated in 20 mM Tris-HCl
buffer, pH 7.5, and eluted with a linear gradient of NaCl (0 to
1 M). The fraction containing the BCO, eluted between 0.25
and 0.35 M NaCl, was subsequently subjected to gel filtration
on an AKTA Superose 12 HR 10/30 column (GE Healthcare
Life Sciences), equilibrated in 0.1 M Tris-HCl buffer (pH 7.5).
This last purification step does not affect the polypeptide pattern
of the protein, but removes unidentified low molecular mass
compounds, resulting in a high pure BCO sample.
Antifungal Agents
The BCO was extracted and purified as described above and
stored lyophilized at room temperature (RT). AMB was obtained
from their respective manufacturers and stock solutions were
prepared and stored frozen at−20◦C until used.
Production of BCO Polyclonal Antibodies
A sample of BCO was lyophilized and ressuspended in Freund
adjuvant. New Zeland female rabbits and rats were immunized
with the purified BCO sample. To obtain a high titer, three
boosters injections of 100 µg/mL of antigen each were given
every 2 weeks in complete Freund’s diluted 1:10 with incomplete
adjuvant. Total blood was taken from the heart 12 days after
the third booster injection. Blood samples were allowed to clot,
and the serum was collected, centrifuged, and stored at −70◦C.
To purify the IgG present in the serum, a chromatography in a
Protein G sepharose column was conducted.
Antifungal Susceptibility Tests
Susceptibility tests were made according to the CLSI – Clinical
and Laboratory Standards Institute (former NCCLS – National
Committee for Clinical Laboratory Standards) guideline M27-
A2 (NCCLS, 2002) with some adjustments, using the broth
microdilution method. Yeast cells were grown on GYP medium
and the inoculum suspension was prepared by picking fresh
colonies and resuspending them in 5 mL of sterile 0.9% (w/v)
saline (NaCl). The resulting suspension was vortexed for 15 s and
the cell density was adjusted with a spectrophotometer to give an
inoculum concentration of 106 cells per mL. The final inoculum
suspension was prepared by a 1:50 dilution followed by a 1:20
dilution with double-strength broth medium, which resulted in a
final concentration of 103 cells per mL. One other final inoculum
concentration was tested in C. albicans, 105 cells/mL, achieved by
a 1:10 dilution with double-strength broth medium, for allowing
a sufficient number of cells to be visualized under the microscope
and to enable the determination of a MFC based on a 99.9%
killing (see Minimum Fungicidal Concentration section below).
The inoculum size was verified by enumeration of CFUs obtained
by subculturing on GYP plates. The solution of the BCO was
prepared in ultrapure sterile water and 200 µL were added to
the first line of the microplate. A serial two-fold dilution was
made, twelve times, using ultrapure sterile water, in the 96-well
microplates. The final concentration of the BCO, after addition
of the inocula, ranged from 0.002 to 4.762 µM when using PDB
medium and from 0.012 to 23.81 µM with RPMI medium. The
serial twofold dilutions of AMB ranged from 0.03 to 17.31 µM.
The yeast inoculum (100 µL) was added to each well of the
microplate, containing 100 µL of the drug solution (twofold
concentrated). The final volume in each well was 200 µL. The
microplate was incubated at 35◦C and examined after 72 h.
Minimum inhibitory concentrations (MICs) are the lowest drug
concentration showing absence of growth, as recorded visually.
To evaluate the effect of sorbitol on the fungal susceptibility
to the BCO, the growth medium (twofold concentrated) was
supplemented with 2.4 M sorbitol (final concentration 1.2 M).
All these tests were performed with three different batches of the
BCO (triplicates).
Minimum Fungicidal Concentrations
(MFCs)
Minimum fungicidal concentrations were determined according
to (Espinel-Ingroff, 1998). After MIC determination, as
previously described, 30 µL aliquots were subcultured from
each well that showed no visual growth onto GYP plates. This
procedure was performed to minimize drug carryover effects
(Espinel-Ingroff, 1998). The plates were incubated at 35◦C for
24 h. All these tests were performed with three different batches
of the BCO (triplicates).
The non-existence of a standard method for determining
MFCs in yeasts as led to an indiscriminate use of a wide range
of methodologies for determining this value (Vazquez et al.,
1997; Johnson et al., 1998; Espinel-Ingroff, 2001). To maintain
the standardized methodology for determining MIC, an initial
inoculum of 103 CFU/mL was used, although it does not allow
the detection of 99.9% killing. To minimize this restriction, the
MFC considered in this study was the lowest drug concentration
where no growth was observed after plating 30 µL on GYP plates
(0 CFUs). For achieving a 99.9% killing an initial inoculum size
of 105 CFU/mL was tested for C. albicans only.
Time-Kill Curves
The effect of the BCO on the growth of human fungal pathogens
was evaluated by using C. albicans as a model organism and by
comparing the results observed with those of AMB, in PDB pH
7.5. The assays were conducted in the presence of different BCO
and AMB concentrations. A cell suspension was grown overnight
in 20 mL of PDB pH 7.5, at 35◦C, 150 rpm and refreshed in 20 mL
of PDB pH 7.5, approximately 5 h before addition to the culture
medium. To obtain an initial concentration of approximately
105 CFU/mL, the OD640 nm was adjusted to 0.1 and then 10-
fold diluted with PDB pH 7.5, to a final volume of 100 mL, in
500 mL Erlenmeyer flaks. The cultures were incubated at 35◦C
without shaking. At regular intervals, samples were collected for
absorbance measurements, viable cell counts and morphological
evaluation. For viable cell counts, 30 µL aliquots of the culture
were taken, diluted if needed, and plated on GYP agar plates. Each
time-kill curve was performed in triplicate and a representative
curve is shown in the results.
Effect of the BCO on Yeast Cell Volume
The effect of the BCO on the yeast cell volume was evaluated
using S. cerevisiae (W303) as a yeast model. Two yeast cultures
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were grown as described in the Time-kill curves section, one
in the presence of the BCO and the other kept as control. At
regular intervals, samples were collected and an estimate of the
cell volume was made, by measuring the diameter of 100 cells.
The cell volume was calculated considering the shape of the cells
as a sphere. At each sampling time the average volume of the
100 cells was calculated as well as the corresponding standard
deviation.
Haemolytic Activity
The haemolytic activity of the BCO was analyzed according to
(Ling et al., 2015). Briefly, fresh red blood cells from rabbit were
collected and washed with PBS until the upper phase was clear
after centrifugation. The pellet was ressuspended in PBS to an
OD600 nm = 24 and added to a 96-well microplate. The solution
of the BCO was prepared in ultrapure sterile water and a serial
twofold dilution was made in water and added to the wells. The
final concentration of the BCO ranged from 0.04 to 4.76 µM.
After 1 h incubation at 37◦C, cells were centrifuged at 1000 g and
the supernatant was diluted and measured at 450 nm in a BioTek’s
Take3TM Multi-Volume Plate spectrophotometer.
Viability Assessments
The LIVE/DEAD
R©
Yeast Viability Kit (Molecular Probes) was
used to evaluate fungal viability. A FUN1 100 µM working
solution was prepared in 10 mM MOPS buffer, pH 7.2, with
2% (w/v) glucose. A 50 µM calcofluor white working solution
was prepared in distilled water. Forty microliter of fungal culture
and 5 µL of FUN1 working solution were mixed thoroughly
and incubated at 30◦C in the dark. After 30 min, 5 µL of
calcofluor white working solution were added to the culture and
mixed thoroughly. Five microliter of the cell culture were trapped
between a microscope slide and a coverslip for visualization on a
fluorescence microscope.
Cell Membrane Integrity
After 24 h incubation with the BCO, under the same conditions
as described in the Time-kill curves section, cells were incubated
with propidium iodide at a final concentration of 7.5 µM, for
10 min at 4◦C. Five microliter of the cell culture were trapped
between a microscope slide and a coverslip, for visualization on a
fluorescence microscope.
Morphological Changes in C. albicans
Cells in the Presence of the BCO
Morphological changes in C. albicans cells in the presence of
the BCO were assessed by Transmission Electron Microscopy
(TEM). The culture was prepared and kept under the same set
of conditions as previously described in the Time-kill curves
section. At regular intervals, samples were collected, washed twice
with saline [9.5% (w/v) NaCl] and concentrated by centrifugation
(3500 g for 10 min) to a final concentration of 1 to 5 × 106
CFU/mL. Cell concentration was confirmed at all points by
plating in GYP agar. The samples were collected and fixed
in 2% (v/v) glutaraldehyde and 2.5% (v/v) paraformaldehyde
in 0.1 M sodium cacodylate buffer pH 7.4. Then, they were
post fixed in 2% (w/v) OsO4, dehydrated and embedded in
epon. The ultrathin-sections (60 nm) were counterstained with
aqueous uranyl acetate solution and lead citrate. Controls were
prepared under the same conditions, but in the absence of
the BCO.
Immunolocalization of the BCO
Immunolocalization of the BCO was accomplished by both
indirect immunofluorescence and immunogold methods. In
both cases the culture was prepared and kept under the same
conditions as previously described in the Time-kill curves
section.
Immunofluorescency studies were accomplished according to
(Lawrence et al., 2004) with some modifications. After 24 h
incubation with a lethal concentration of the BCO, the culture
was concentrated by centrifugation (3500 g for 10 min) to a final
concentration of 1 to 5 × 107 CFU/mL followed by treatment
with lyticase (0.4 mg/mL in 500 mM Tris-HCl, 1 M sorbitol, 0.8
M KCl, 10 mM MgS04, pH 7.5) for 2 h at 30◦C, to digest the cell
wall, allowing the subsequent cell membrane permeabilization.
The culture was washed with PBS (137 mM NaCl, 1.5 mM
KH2PO4, 8.1 mM Na2HPO4 and 2.7 mM KCl) followed by
fixation in 4% (v/v) formaldehyde, for 30 min, at 30◦C. After
two washes with PBS and PBS containing 0.1% (v/v) Triton X-
100 for cell membrane permeabilization, cells were blocked with
bovine serum albumine (BSA) 5% (w/v) in PBS containing 0.1%
(v/v) Triton X-100 for 30 min. Cells were washed with PBS and
incubated with the first antibody (anti-BCO), produced in rabbit
and diluted 1:500 in PBS containing 0.1% (v/v) Triton X-100 and
0.1% (w/v) BSA, for 16 h at 4◦C. The cells were then washed in
PBS and incubated with a second, anti-rabbit antibody, produced
in goat, conjugated with FITC and diluted 1:80 in PBS with 1%
(w/v) BSA, for 1 h at 37◦C. After washing twice with PBS for
15 min, 50 µM calcofluor white were added and 5 µL of the cell
culture were trapped between a microscope slide and a coverslip,
for visualization on a confocal microscope.
For immunogold analysis, the samples were collected after
6, 12, and 24 h of incubation with the BCO and subsequently
fixed in 0.1% (v/v) glutaraldehyde in 0.1 M sodium cacodylate
buffer pH 7.4 for 1 h. Then, they were dehydrated and embedded
in LRWhite. Thin sections on TBS were immunolabeled after
incubation on etching process: grids were incubated in a humid
chamber in large drops of a saturated aqueous solution of
sodium metaperiodate, for 1 h at RT. After washing the grids,
they were first incubated for 20 min in 2% (w/v) gelatin in
TBS, and a second 5 min incubation was done with 15 mM
glycine. The grids were blocked with a solution containing 2%
(w/v) immunoglobulin-free BSA. Sections were then incubated
overnight (16–18 h) with the first antibody (anti-BCO) diluted
1:250 in TBS containing 2% (w/v) BSA and 1% (v/v) Tween-
20/3% (w/v) NaCl. The grids were then washed by floating them
on drops of 0.1% (w/v) BSA /TBS (four changes, 2 min each)
followed by 20 min incubation on TBS with 1% (w/v) BSA. Bound
antibodies were visualized by incubating the sections for 1 h with
the second antibody-gold conjugate (10 nm diameter particles)
diluted 1:25 in PBS with 1% (w/v) BSA, 1% (v/v) TBS. Finally,
grids were washed on drops of water (six changes, 10 min each).
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The immune-complexes formed were visible as little black dots
when observed by TEM.
Microscopy
(I) Fluorescence microscopy. Samples were observed under a
fluorescence microscope (Axioscope A1 with phase contrast
and epi-fluorescence, Zeiss) equipped with a camera (AxioCam
ICm1, Zeiss), using three different filters: Filter Set 49 DAPI
(Excitation G 365, Emission BP 420/470); Filter Set 10 FITC/GFP
(Excitation BP 450-490, Emission BP 515-565) and Filter Set
15 Rodhamine (Excitation BP 540-552, Emission LP 590). (II)
Confocal microscopy. The images were acquired with a Leica TCS
SP5 II confocal microscope equipped with an objective HCX
PL APO CS 63x/1.3 Glycerol (Leica Microsystems, Germany).
Samples were excited by 488 nm laser line and emitted signal
detected in the range of 496-564 nm with a HyDet detector
(fluorescence channel) and a PMT detector (transmission
channel). Images were acquired with 512 × 512 pixels and a
pixel size of 68 nm. (III) Transmission electron microscopy. The
sections were examined under a JEOL JEM 1400 TEM 120kV
(Tokyo, Japan). Images were digitally recorded using a CCD
digital camera Orious 1100W Tokyo, Japan.
RESULTS
Determination of Minimum Inhibitory and
Fungicidal Concentrations
The antifungal activity of three different batches of the BCO was
evaluated in six strains belonging to six Candida species and in
one strain of C. neoformans, with each strain cultured in two
different growth media. C. albicans CBS 562 was also tested for
resistance to AMB, one commonly used antifungal drug. The
MICs and MFCs of the BCO are shown in Table 1. MIC values in
RPMI medium for the entire group varied from 0.19 to 2.98 µM.
Regarding the MFCs of the BCO, the values obtained were higher
than the highest concentration tested. The exception was the
strain of C. albicans, for which the MFC of the BCO was 23.81µM
(Table 1).
When the antifungal activity of the BCO was assessed in
PDB medium, the MIC and MFC values obtained were more
consistent among the different species, which is in accordance
TABLE 2 | Ranges of MIC and MFC values of the BCO and AMB for
C. albicans (in PDB medium at pH 7.5), with an initial inoculum of 105
CFU/mL and tested with three different batches of the BCO.
Antifungal agent MIC (µM) MFC (µM)
BCO 0.60–1.19 1.19–2.38
AMB 1.1 2.2
with previous studies that demonstrated that PDB is a more
suitable medium for testing the bioactivity of this oligomer
(Monteiro et al., 2015). All strains tested presented a similar
susceptibility to the BCO, with MIC values ranging from 0.08
to 0.31 µM (Table 1). Regarding the MFCs of the BCO in PDB
medium, the values varied from 0.15 to 2.38 µM. For the strains
of C. albicans, C. dubliniensis and C. neoformans, the MFCs
were always only twice of the respective MICs and for those of
C. glabrata and C. lusitaneae were always four times higher. The
MFC of BCO for C. parapsilosis was too much higher than the
other ones (2.38 µM) (Table 1). Overall the results obtained for
the BCO are indicative of a potent antifungal activity for these
fungal species.
The antifungal activity of the BCO was then compared to that
exhibited by AMB, in PDB medium, using C. albicans as a control
model. This specie has long been used as a model in several
fungal research studies (Fu et al., 2008; Kabir et al., 2012), and
also showed a strong susceptibility to the BCO, as demonstrated
by the corresponding MIC and MFC values (Table 1). Since the
optimum inoculum density for the subsequent microscopy tests
was found to be 105 CFU/mL, and since this concentration allows
the detection of a 99.9% killing based MFC, both minimum
inhibitory and fungicidal concentrations were determined with
this inoculum size. The results are presented in Table 2. As
expected, there was an increase in MIC and MFC values, due
to a higher number of cells in the initial inoculum. However,
these results are still consistent with those obtained before
(Table 1). The concentration of the BCO needed to induce
death of 99.9% of the microorganisms was only twice the MIC
(0.60–1.19 and 1.19–2.38 µM, respectively). The same effect
was observed for AMB (MIC and MFC values of 1.1 and
2.2 µM, respectively), which is also consistent with the values
reported in the literature (Manavathu et al., 1998; Spreghini et al.,
2012).
TABLE 1 | Ranges of MIC and MFC values of the BCO for various yeast species grown in two different culture media, with an initial inoculum of 103
CFU/mL and tested with three different batches of the BCO.
RPMI medium PDB medium
Yeast Species MIC (µM) MFC (µM) MIC (µM) MFC (µM)
Candida albicans 1.49 23.81 0.15–0.31 0.31–0.61
Candida dubliniensis 0.75–1.49 >23.81 0.15–0.31 0.31–0.61
Candida glabrata 0.19–0.37 >23.81 0.08–0.15 0.31–0.61
Candida lusitaneae 0.37 >23.81 0.15–0.31 0.61
Candida parapsilosis 0.37 >23.81 0.15–0.31 2.38
Candida tropicalis 2.98 >23.81 0.15 0.61
Cryptococcus neoformans 0.37 >23.81 0.08–0.15 0.15–0.31
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BCO Leads to an Increase on the Yeast
Cell Volume Unrelated to Major Cell Wall
Disturbances
Given the demonstrated affinity of the BCO to chitin (Monteiro
et al., 2015), two studies were conducted for assessing its possible
effect in cell wall biosynthesis. S. cerevisiae was used as the model
organism for these studies. The cells were exposed to BCO at
the MIC value and an estimate of the cell volume at three-time
sampling points was made. The results obtained are described
in Figure 1 and show that the presence of the BCO leads to
a progressive increase in the average volume of the cells. The
volume variation between the first and the last sample analyzed
is higher than 10 fold (147 µm3 after 1 h of incubation and
1621 µm3 after 48 h).
Considering the results above, if the BCO mode of action is at
least in part based on cell wall damage, it is expected for the cell
to suffer an increase of volume under hypotonic conditions, until
eventually bursts. If this is the case, under isotonic conditions,
or even in a slightly hypertonic medium, this effect should not
occur, since there is no water entering into the cells. With the
purpose of testing if the osmotic stabilizer sorbitol counteracts
the toxicity of the BCO, 1.2 M sorbitol was added to the culture
medium (creating a slightly hypertonic condition). Tests were
carried out in the absence and in the presence of 1.2 M sorbitol
in S. cerevisiae. The results demonstrated that the presence of 1.2
M sorbitol in the culture medium did not reduce the antifungal
effect of the BCO, since the MIC values were the same in both
cases (0.15 µM). This result suggests that ultimately, the toxicity
of the BCO to fungi is not dependent on dramatic changes in cell
wall integrity despite its ability to bind very tightly to the chitin
polymer (Monteiro et al., 2015).
BCO Has a Dose-Dependent Effect on
the Growth of C. albicans
Determination of the “killing” of an isolate over time by one
or more antimicrobial agents under controlled conditions is
known as the time-kill method (Pfaller et al., 2004). It is
a broth based method where the rate of killing of a fixed
inoculum is determined by sampling control (organism, no
drug) and antimicrobial agent-containing tubes or flasks, at
certain time intervals, and determining the survivor colony
count (CFU/mL) by spreading each sample onto an agar plate.
In order to study the effect of the BCO on the growth of
C. albicans, time-kill curves were performed in PDB medium.
Several samples were taken during these experiments in order
to assess the evolution of the number of viable cells (OD640 nm
and CFU counts). Two concentrations of BCO were used, 1.19
and 2.38 µM, corresponding to the minimum inhibitory and
fungicidal concentrations, respectively, as determined previously
(Table 2). A fraction of the culture grown under the same
conditions but without BCO was tested for control purposes. The
results are shown in Figure 2 for the BCO and in Figure 3 for
AMB.
Figure 2 shows that the addition of BCO to the culture
medium had a strong effect in the growth of C. albicans. It is
possible to observe that the culture grown in the absence of
BCO presents a normal growth curve, being in the exponential
phase of growth for approximately 12 h, before entering
the stationary phase. This was observed by following both
OD640 nm readings and CFU/mL counts. Cells grown in the
presence of the MIC of the BCO, showed a decrease in the
growth rate when compared to the control, which resulted
in a lower final optical density (Figure 2A) and a lower
FIGURE 1 | Blad-containing oligomer (BCO) effect on S. cerevisiae W303 cell volume along time. S. cerevisiae cells were grown in YNB medium
supplemented with 2% (w/v) glucose, pH 7.0, at 30◦C. The horizontal bars show the mean values (central bar) and the standard deviation (edge bars). (A) – culture
kept without the BCO; (B) – culture with 0.152 µM BCO.
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FIGURE 2 | Effect of the BCO on the growth of C. albicans in PDB medium, pH 7.5, 35◦C, without agitation (representative curve of triplicate
experiments). (A) OD640 nm (B) CFU/mL. BCO concentration in the culture medium: 0 µM (u), 1.19 µM () and 2.38 µM (N).
FIGURE 3 | Effect of AMB on the growth of C. albicans in PDB medium, pH 7.5, 35◦C, without agitation (representative curve of triplicate
experiments). (A) OD640 nm (B) CFU/mL. AMB concentration in the culture medium: 0 µM (u), 1.1 µM () and 2.2 µM (N).
final CFU/mL count (Figure 2B). This result indicates that
the concentration of the BCO tested had, indeed, the ability
to inhibit the growth of this microorganism. Cells grown in
the presence of the minimum fungicidal concentration became
non-viable after 16 h of growth. This was observed by both
stabilization of OD640 nm, just after 4 h of incubation (Figure 2A),
after a slight initial growth, and absence of CFU counts
(Figure 2B).
The same assay was performed using AMB as the antifungal
agent. Two different concentrations were also used, 1.1
and 2.2 µM, corresponding to the minimum inhibitory and
fungicidal concentration, respectively. The results obtained were
very similar to those obtained for the BCO and are shown
in Figure 3. The control fraction stayed in exponential phase
for 12 h, and the fraction exposed to the MIC showed a
total absence of growth. When using the minimum fungicidal
concentration of AMB cells became non-viable in the first 4 h
of exposure, which was observed by the absence of CFU counts
(Figure 3B). The prompt reduction in C. albicans viability
caused by AMB is in accordance with the data published in
the literature (Cantón et al., 2004; Leite et al., 2014). The
major difference between the BCO and AMB in terms of killing
kinetics is that both fungistatic and fungicidal activities of AMB,
under these conditions, act more rapidly than those of the
oligomer.
The MFC of the BCO Induces a Severe
Decrease on the Metabolic Activity in
C. albicans
The effect of the BCO on the viability and cellular integrity
of yeasts was evaluated using C. albicans as model and was
assessed using samples collected along the growth curve, in
PDB medium, under three different conditions: without drug
(control), with the inhibitory (MIC) concentration (1.19 µM)
and with the lethal (MFC) concentration (2.38 µM). Each sample
was stained with FUN-1 and calcofluor white and visualized
in a fluorescence microscope. FUN-1 binds to nucleic acids
producing a yellowish green fluorescence in death cells with
a damaged membrane. Cells without metabolic activity but
with an intact plasma membrane also present a diffuse green
coloration in the cytoplasm. On the other hand, in metabolically
active cells, formation of orange cylindrical structures designated
CIVS (Cylindrical IntraVacuolar Structures) is observed inside
vacuoles. CIVS formation only occurs in metabolically active cells
with an intact plasma membrane, meaning they are not observed
in dead cells (Chew et al., 2015). Calcofluor white is a compound
with high affinity to chitin and is normally used as a marker of the
fungal cell wall. The results are shown in Figures 4 and 5.
Figure 4 suggests that during the first 4 h of incubation with
the BCO there are no changes regarding the viability and integrity
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FIGURE 4 | Effect of the BCO on the metabolic activity and cellular integrity of C. albicans cultivated in PDB medium, pH 7.5, at 35◦C, without
agitation. Samples were taken after 4 h of incubation. Concentration of the BCO in the culture medium: 1 – 0 µM, 2 – 1.19 µM, 3 – 2.38 µM. Labeling with FUN-1
(A), calcofluor white (B), and bright field microscopy (C). Bar corresponds to 10 µm.
of the cells, for all conditions tested, since the presence of CIVS
indicates metabolic activity and the fluorescence with calcofluor
white is normal and equal to the control fraction, indicating cell
wall integrity. These results are consistent with the ones obtained
in the growth curves (Figure 2).
After 12 h of incubation with the BCO, the control fraction
continued to exhibit CIVS in the majority of the cells, confirming
that they were still metabolically active. The fraction incubated
with an inhibitory concentration of the BCO showed a slight
lower number of cells with CIVS, meaning that some cells were
metabolically active and, therefore viable and culturable, thus
explaining the small increase in the OD640 nm and CFU counts
observed in the curve of Figure 2. At 12 h, cells incubated with
the lethal concentration of the BCO presented very few CIVS,
corresponding to a decrease in the metabolic activity (data not
shown). This explains the decrease also observed in the CFU
counts observed in Figure 2.
Microscopical observations performed at 16 h of incubation
revealed to be a turning point in cell viability, which is in
accordance to what is also observed with other antifungal drugs
(Kim et al., 2011). Although both the control and MIC fractions
of the BCO showed no changes as compared to the previous time
point studied, the culture incubated with a lethal concentration
of the BCO no longer presented visible CIVS. Only a diffuse
green coloration in the cytoplasm was visible, corresponding to
the absence of metabolic activity (Figure 5). However, when
cultivated in a free BCO medium some cells were still able
to grow (Figure 2B). At 24 h of incubation, the last time
point studied, the control fraction presented some cells without
CIVS, typical of an old culture and the MIC fraction presented
even fewer metabolically active cells than in the previous time
point studied (data not shown). This is in accordance with
the stabilization of OD640 nm and with the smaller number
of culturable cells observed in the growth curves (Figure 2).
The results obtained with the lethal concentration of the BCO
were similar to those obtained after 16 h (cells without any
metabolic activity), but at this point there were also no records
of culturable cells (Figure 2B). This means that approximately
between 16 to 24 h of incubation with a lethal concentration
of the BCO, C. albicans lost the ability to grow in a free BCO
medium, and that the number of culturable cells was beneath
the detection limit of the method (<10 CFU/mL). These results
suggest that after 16 h of incubation with a lethal concentration
of the BCO, cells are metabolically inactive (Figure 5), non-
viable and non-culturable (Figure 2). During these periods, the
integrity of the cell wall remained unchanged regardless of the
concentration of the BCO tested, as showed by calcofluor white
staining (Figures 4 and 5).
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FIGURE 5 | Effect of the BCO on the metabolic activity and cellular integrity of C. albicans cultivated in PDB medium, pH 7.5, at 35◦C, without
agitation. Samples were taken after 16 h of incubation. Concentration of the BCO in the culture medium: 1 – 0 µM, 2 – 1.19 µM, 3 – 2.38 µM. Labeling with FUN-1
(A), calcofluor white (B), and bright field microscopy (C). Bar corresponds to 10 µm.
BCO Induces Cell Membrane Damages
Cell membrane integrity was evaluated with propidium iodide.
This compound binds to DNA and RNA producing a red
fluorescence when intercalated with nucleic acids. However, due
to its positive charge, it cannot cross an intact cell membrane
and, therefore, only dead cells or cells with a damaged membrane
are stained. Propidium iodide staining was evaluated at 24 h of
incubation of C. albicans with the inhibitory (MIC) and with the
lethal (MFC) concentration of the BCO, as determined previously
(1.19 and 2.38 µM, respectively). The results, shown in Figure 6,
clearly indicate that the BCO somehow destabilizes the plasma
membrane, enabling the entrance of the fluorescent dye into the
cell.
BCO Moves from the Cell Wall into the
Interior of the Cell
Immunofluorescence is a technique that allows the visualization
of antigen-antibody interactions in cell suspensions. To this
end, the BCO was used as the antigen since a first anti-BCO
antibody produced in rabbit is then added, followed by a second
anti-rabbit antibody produced in goat, conjugated with FITC.
In this particular case, C. albicans was incubated with a lethal
concentration of the BCO (2.38 µM) in PDB pH 7.5 medium
for 24 h and observed by confocal microscopy. Calcofluor white
was also added to assess the efficiency of the cell wall digestion.
The results are presented in Figure 7 and show a clear green
fluorescence inside the cell. Control without the BCO was also
tested and no green fluorescence was observed (data not shown).
This result suggests that after 24 h of incubation, the BCO was
able to cross the cell envelope and is clearly inside the cells.
The calcofluor white staining indicates that not all the cell wall
was efficiently digested (Figure 7C). However, it was sufficient
to allow the cell membrane permeabilization and the subsequent
entrance of the antibodies.
To confirm these results we next proceeded with immunogold
labeling. As before, cells were exposed to a lethal concentration of
the BCO for 24 h and samples were collected after 2, 6, 12, and
24 h of incubation. Each sample was analyzed by immunogold
using anti-BCO produced in rat as the first antibody and a
second anti-rat antibody coupled to gold particles. The immune-
complexes formed were visible as little black dots when observed
by TEM (Figure 8). At each sampling point, including time zero,
the controls without the BCO were also tested and no black dots
were found in none of the controls tested (data not shown). The
analysis of Figure 8 shows that the BCO progressively moves
from the cell wall into the interior of the cell. Shorter incubation
periods show the protein preferentially agglomerating near the
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FIGURE 6 | Effect of the BCO on the viability and membrane integrity
of C. albicans cultivated in PDB medium, pH 7.5, at 35◦C, without
agitation. Samples were taken after 24 h of incubation. Concentration of the
BCO in the culture medium: 1 – 0 µM, 2 – 1.19 µM and 3 – 2.38 µM.
Labeling with propidium iodide (A), and bright field microscopy (B). Bar
corresponds to 10 µm.
cell wall (Figures 8A,B), while longer incubation periods show a
migration of the BCO to the cytosol and even to the interior of
vacuoles (Figures 8C,D).
C. albicans Suffers Several
Morphological Changes in the Presence
of the BCO
The morphological changes undergone by C. albicans after
exposure to the BCO, were evaluated by TEM. Cells were exposed
to a lethal concentration of the BCO for 48 h and samples were
collected at 0, 24, and 48 h. The results are presented in Figure 9.
Figure 9A shows a section of a well preserved C. albicans cell,
presenting a homogeneous cytoplasm, with an external fibrillar
layer (f), a compact cell wall and a normal plasma membrane
(cm). After 24 h incubation with the lethal concentration of
the BCO, several morphological changes are visible (Figure 9B),
mainly focused between the cell wall and the cell membrane.
These changes became more clear after 48 h of incubation with
a lethal concentration of the BCO, where it is visible an increased
thickness at the cell wall level (Figure 9C), appearance of
small vesicles in the periplasmatic region (Figure 9D), abnormal
density and shape of the cell wall (Figure 9D), an accumulation
of high density vacuoles in the cytoplasm (Figure 9E) and cell
wall disruption, only visible in some buds (Figure 9F). Although
the population of cells showed some heterogeneity, in general,
the cells that presented more structural changes also displayed
an increased size. The controls performed in the absence of the
BCO showed none of these characteristics at the corresponding
harvesting times (data not shown).
Absence of Haemolytic Activity
The interaction of the BCO with mammalian red blood cells
was studied by haemolysis experiments. Erythrocytes were
incubated with different concentrations of the BCO, ranging
from 0.04 to 4.76 µM for 1 h at 37◦C. BCO showed no
haemolytic effects up to 4.76 µM (data not shown), which
is indicative of no detectable interference of the red blood
cells.
DISCUSSION
The data presented above clearly show that the BCO has
antifungal activity against a wide range of human yeasts
pathogens, namely, C. albicans, C. dubliniensis, C. glabrata,
C. lusitaneae, C. parapsilosis, C. tropicalis and C. neoformans.
The antifungal activity of the BCO was compared to that of
AMB, a commonly used human antifungal agent, and the results
demonstrate that the concentrations needed to induce both
cellular inhibition and cellular death are very similar to those
referenced for AMB (Cantón et al., 2004; Sabatelli et al., 2006;
Cordeiro et al., 2013). The BCO has already a sustained efficacy
proved against phytopathogenic fungi, both under in vitro assays
and in field trials (Monteiro et al., 2015), but this is the first
report that demonstrates its activity against unicellular human
pathogenic fungi.
Similarly to other antifungal compounds such as Congo
red, caffeine or caspofungin, several antifungal peptides (e.g.,
defensins) and proteins from Aspergillus species are known
to interfere with cell wall biosynthesis, thus weakening it by
activation of the cell wall integrity pathway (CWIP) and by
inhibiting chitin synthesis. Given the proven affinity of the BCO
to chitin (Monteiro et al., 2015), the presence of the osmotic
stabilizer sorbitol should have resulted in a significant reduction
of the BCO antifungal activity if, in the end, the CWIP was
its first target. However, the presence of 1.2 M sorbitol in
the culture medium did not reduce the antifungal effect of
the BCO suggesting that ultimately, the toxicity of the BCO
is not directly related to dramatic changes caused in cell wall
integrity.
All bioactivities described for the BCO up until now, were only
focused on the fungal cell wall (Monteiro et al., 2015). However,
chitinase and β-1,3-glucanase activities were not detected in the
BCO, which apparently limits its ability to cleavage the cell wall
of fungi. β-1,3-glucanase has been reported to partially digest
the cell walls of Verticillium albo-atrum, and this degradation
seems to be synergistically stimulated by chitinase (Skujins
et al., 1965). Chitinases have long been reported to hydrolyse
chitin from the cell walls of some fungal pathogens and non-
pathogens in vitro (Skujins et al., 1965; Boller et al., 1983;
Schlumbaum et al., 1986), and β-N-acetyl-D-glucosaminidase is
only able to complete the degradation of chitin by hydrolyzing
the soluble oligosaccharides to monosaccharides. β-N-Acetyl-D-
glucosaminidase, one of the enzymatic activities displayed by the
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FIGURE 7 | Immunofluorescence in C. albicans incubated with a lethal concentration of the BCO for 24 h and visualized by confocal microscopy.
Cells were treated with lyticase before fixation. BCO functions as the antigen; first antibody: anti-BCO produced in rabbit; second antibody: anti-rabbit produced in
goat, conjugated with FITC. Bright field microscopy (A), bright field microscopy merged with FITC filter (B), DAPI filter (C). Bar corresponds to 10 µm.
BCO (Monteiro et al., 2015) catalyzes the progressive release of
N-acetyl-D-glucosamine from the non-reducing end of chitin,
and together with chitinases are considered a very effective
chitinolytic system on fungi (Silva et al., 2004). For example,
in Trichoderma harzianum this system is suggested to play an
important role in its potential use as a biocontrol agent against
several phytopathogenic fungi (Haran et al., 1996). Chitosanase
activity of the BCO is the endohydrolysis of β-1,4 linkages
between N-acetyl-D-glucosamine and D-glucosamine residues
in partially deacetylated fungal cell wall chitosan polymer.
This should not to be confused with chitinase activity, which
is the random endohydrolysis of N-acetyl-β-D-glucosaminide
β(1,4) linkages in chitin and chitodextrins. Chitosan is the
deacetylated version of chitin, and may possess different degrees
of deacetylation (Tsigos et al., 2000). Chitosan is present in the cell
wall of a small number of fungi (mainly zygomycetes), conferring
structural integrity (Baker et al., 2007). C. albicans cell wall,
like many other fungi, does not contain chitosan, so we were
not expecting to see any particular rupture in the microscopic
observations with calcofluor white (a specific cell wall marker for
fungi, due to its chitin affinity). However, some destabilization
of the cell wall structure may occur, without any visual effect
by fluorescent labeling, due to its β-N-acetyl-D-glucosaminidase
activity, at the end of the chitin polymer. In fact, the absence of
visual damages at the cell wall does not imply a fully operational
and structured wall, as the same can be observed even with cell
wall-targeting drugs (Piotrowski et al., 2015). This might explain
why the cell wall remained visually intact with calcofluor white
staining, while the cells were becoming metabolically inactive,
or even dead. A certain degree of disturbance in the cell wall
structure seems to be required to allow the entrance of the
210 kDa oligomer. Furthermore, a clear disruption of the cell
wall was observed in some bud cells. Nevertheless, the antifungal
activity of the BCO does not seem to be related to the cell
wall integrity, as demonstrated previously with the sorbitol test
result.
Damages at the cell membrane level, measured by propidium
iodide uptake, are usually indicators of cell death (Simonin et al.,
2007; Choi et al., 2012), but it is also possible that some damaged
cells retain the ability to recover after a short incubation (Davey
and Hexley, 2011). Propidium iodide may also be used as an
indicator of cell leakage, or cell permeability (Piotrowski et al.,
2015). In any case, it was here demonstrated that BCO induces
cell membrane damage in C. albicans, and this surely contributes
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FIGURE 8 | Immunogold localization in C. albicans after incubation
with the BCO for (A) 2 h, (B) 6 h, (C)12 h and (D) 24 h, as observed by
TEM. The black dots represent the localization of the BCO in the cells.
to its inhibitory and/or lethal effect on cells. Nevertheless, and
once again, this does not seem to be its primary mode of
action.
Regarding the localization of the BCO in the cell, the
results obtained by both immunofluorescence and immunogold
labeling definitely indicate that the BCO enters the cell,
although the mechanism underlying such entry is still unclear,
especially considering its large molecular size (210 kDa).
However, C. albicans is known to internalize large molecules
similarly to other fungi (Riezman, 1985; Basrai et al., 1990;
Helmerhorshmt et al., 2001; Oberparleiter et al., 2003; Theis
et al., 2005), and such mechanism can explain the transport
of the BCO into the cytosol. There are also reports of
antifungal proteins being internalized by fungal cells, like
NaD1 (Van Der Weerden et al., 2008, 2010), MtDef4 (Sagaram
et al., 2013) and Psd1 (Lobo et al., 2007). There are several
mechanisms by which these proteins can be internalized by
the cell, such as receptor-mediated internalization, membrane
translocation and membrane permeabilization (Vriens et al.,
2014).
Many of the morphological changes observed in C. albicans
cells upon exposure to a lethal concentration of the BCO,
namely thickening of the cell wall and an increased cell size,
which are the most striking features, were already observed
in yeast species as a response to various stressful conditions
such as halophilic stress (Kuncic et al., 2010; Gao et al.,
2014) and exposure to some antifungal drugs (Ishida et al.,
2009; Rueda et al., 2014). For example, in S. cerevisiae,
the presence of salt stress causes an abnormal cell wall
structure, becoming uneven and thicker, with certain areas
clearly damaged (Gao et al., 2014), similarly to what was
observed for C. albicans and the BCO. It is likely that the
ultrastructural alterations described in this study also result
from some chemical stress, at the osmotic level. Regarding
the BCO, some experiments demonstrate that this oligomer
displays a divalent-chelating activity for several cations. This
biochemical property may selectively disturb the essential
divalent cation metabolism of the microorganism by interfering
with metal acquisition and bioavailability for crucial reactions.
This chelation activity could ultimately disturb the microbial cell
FIGURE 9 | Morphological changes after exposing C. albicans to a lethal concentration of the BCO as observed by TEM. Samples were collected and
visualized at times (A) 0 h, (B) 24 h and (C–F) 48 h. f, fibrillary layer; cm, plasma membrane.
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homeostasis and culminate in the blockage of microbial nutrition,
growth and development (Santos et al., 2012).
CONCLUSION
We demonstrate that after being exposed for more than 16 h
to a lethal concentration of the BCO, C. albicans became
metabolically inactive, non-viable and non-culturable. Moreover,
some cells showed loss of cell membrane integrity, but with
no visible rupture of the cell wall, except in bud cells. The
ultrastructural alterations observed suggest that BCO imposes
stressful conditions upon the fungal cell, which ultimately lead
to the cell death. The disturbances observed at the cell wall
and membrane seem to be just a part of a more complex
mode of action of the BCO. In the future more studies are
required in order to fully understand this complex mode of
action, specifically its primary targets within the cell and the
physiological mechanisms underlying cell death. The exceptional
antifungal activity of the BCO, combined with its natural and
edible origin, and the absence of haemolytic activity, provide
a solid background to further investigate its potential as a
novel antifungal therapeutic drug. Its current success as a
phytopharmaceutical drug is already a good indicator to pursuit
this goal. Furthermore, its predictable multisite mode of action
suggests a low risk of inducing resistance mechanisms, which are
now a major problem with other currently available antifungal
drugs.
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